Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 1,826

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy

for the Hepatitis C Study, Suppiah, Vijayaprakash, Moldovan, Max, Ahlenstiel, Golo, Berg, Thomas, Weltman, Martin, Abate, Maria Lorena, Bassendine, Margaret, Spengler, Ulrich, Dore, Gregory J, Powell, Elizabeth, Riordan, Stephen, Sheridan, David, Smedile, Antonina, Fragomeli, Vincenzo, Müller, Tobias, Bahlo, Melanie, Stewart, Graeme J, Booth, David R, George, Jacob·2009·Nature Genetics
DOI 10.1038/ng.447
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/ng.447

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Research works printed but not linked: 42

  1. Micallef, J.M., Kaldor, J.M. & Dore, G.J. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J. Viral Hepat. 13, 34–41 (2006). · DOI · Paper page
  2. Hoofnagle, J.H. Course and outcome of hepatitis C. Hepatology. 36, S21–S29 (2002). · DOI · Paper page
  3. Thomas, D.L. & Seeff, L.B. Natural history of hepatitis C. Clin. Liver Dis. 9, 383–398, vi (2005). · DOI · Paper page
  4. Di Bisceglie, A.M. & Hoofnagle, J.H. Optimal therapy of hepatitis C. Hepatology. 36, S121–S127 (2002). · DOI · Paper page
  5. David, M. Signal transduction by type I interferons. Biotechniques (Oct), S58–S65 (2002). · DOI
  6. Der, S.D., Zhou, A., Williams, B.R. & Silverman, R.H. Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays. Proc. Natl. Acad. Sci. USA 95, 15623–15628 (1998). · DOI · Paper page
  7. de Veer, M.J. et al. Functional classification of interferon-stimulated genes identified using microarrays. J. Leukoc. Biol. 69, 912–920 (2001). · DOI · Paper page
  8. Taylor, M.W. et al. Global effect of PEG-IFN-alpha and ribavirin on gene expression in PBMC in vitro. J. Interferon Cytokine Res. 24, 107–118 (2004). · DOI
  9. Tan, H. et al. Global transcriptional profiling combination of type I and type II demonstrates the interferon enhances antiviral and immune responses at clinically relevant doses. J. Interferon Cytokine Res. 25, 632–649 (2005). · DOI
  10. Taylor, M.W. et al. Changes in gene expression during pegylated interferon and ribavirin therapy of chronic hepatitis C virus distinguish responders from non-responders to antiviral therapy. J. Virol. 81, 3391–3401 (2007). · DOI
  11. Fried, M.W. et al. A multicenter, randomized trial of daily high-dose interferon-alfa 2b for the treatment of chronic hepatitis c: pretreatment stratification by viral burden and genotype. Am. J. Gastroenterol. 95, 3225–3229 (2000). · doi:10.1111/j.1572-0241.2000.03433.x
  12. Manns, M.P. et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 358, 958–965 (2001). · DOI · Paper page
  13. Fried, M.W. et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 347, 975–982 (2002). · DOI · Paper page
  14. Hadziyannis, S.J. et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann. Intern. Med. 140, 346–355 (2004). · DOI · Paper page
  15. Zeuzem, S. et al. Expert opinion on the treatment of patients with chronic hepatitis C. J. Viral Hepat. 16, 75–90 (2009). · DOI · Paper page
  16. Kraft, P. et al. Beyond odds ratios--communicating disease risk based on genetic profiles. Nat. Rev. Genet. 10, 264–269 (2009). · DOI
  17. Weiss, S.T. et al. Creating and evaluating genetic tests predictive of drug response. Nat. Rev. Drug Discov. 7, 568–574 (2008). · DOI
  18. Selzner, N. & McGilvray, I. Can genetic variations predict HCV treatment outcomes? J. Hepatol. 49, 494–497 (2008). · doi:10.1016/j.jhep.2008.07.006
  19. Aurora, R., Donlin, M.J., Cannon, N.A. & Tavis, J.E. Genome-wide hepatitis C virus amino acid covariance networks can predict response to antiviral therapy in humans. J. Clin. Invest. 119, 225–236 (2009).
  20. Samarajiwa, S.A., Forster, S., Auchettl, K. & Hertzog, P.J. INTERFEROME: the database of interferon regulated genes. Nucleic Acids Res. 37, D852–D857 (2009). · DOI · Paper page
  21. de Bakker, P.I.W. et al. Efficiency and power in genetic association studies. Nat. Genet. 37, 1217–1223 (2005). · DOI · Paper page
  22. Li, M., Liu, X., Zhou, Y. & Su, S.B. Interferon-lambdas: the modulators of antivirus, antitumor, and immune responses. J. Leukoc. Biol. 86, 23–32 (2009). · DOI
  23. Mihm, S. et al. Interferon type I gene expression in chronic hepatitis C. Lab. Invest. 84, 1148–1159 (2004). · doi:10.1038/labinvest.3700135
  24. Fox, B.A., Sheppard, P.O. & O'Hara, P.J. The role of genomic data in the discovery, annotation and evolutionary interpretation of the interferon-lambda family. PLoS One 4, e4933 (2009). · DOI
  25. Coccia, E.M. et al. Viral infection and Toll-like receptor agonists induce a differential expression of type I and lambda interferons in human plasmacytoid and monocyte-derived dendritic cells. Eur. J. Immunol. 34, 796–805 (2004). · DOI · Paper page
  26. Ank, N. et al. Lambda interferon (IFNλ), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo. J. Virol. 80, 4501–4509 (2006). · DOI · Paper page
  27. Doyle, S.E. et al. Interleukin-29 uses a type 1 interferon-like program to promote antiviral responses in human hepatocytes. Hepatology. 44, 896–906 (2006). · DOI · Paper page
  28. Sommereyns, C. et al. IFN-lambda is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo. PLoS Pathog. 4, e1000017 (2008). · DOI · Paper page
  29. Ank, N. et al. An Important Role for Type III Interferon (IFNλ/IL-28) in TLR-Induced Antiviral Activity. J. Immunol. 180, 2474–2485 (2008). · DOI · Paper page
  30. Marcello, T. et al. Interferons a and l inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology. 131, 1887–1898 (2006). · DOI · Paper page
  31. Sirén, J. et al. IFN-a regulates TLR-dependent gene expression of IFN-a, IFN-b, IL-28 and IL-29. J. Immunol. 174, 1932–1937 (2005). · DOI
  32. Robek, M.D. et al. Lambda interferon inhibits hepatitis B and C virus replication. J. Virol. 79, 3851–3854 (2005). · DOI · Paper page
  33. Sheppard, P. et al. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat. Immunol. 4, 63–68 (2003). · DOI · Paper page
  34. Österlund, P.I. et al. IFN regulatory factor family members differentially regulate the expression of type III IFN (IFN-lambda) genes. J. Immunol. 179, 3434–3442 (2007). · DOI · Paper page
  35. Dellgren, C. et al. Human interferon-lambda3 is a potent member of the type III interferon family. Genes Immun. 10, 125–131 (2009). · DOI · Paper page
  36. Zhu, H. & Liu, C. Interleukin-1 inhibits hepatitis C virus subgenomic RNA replication by activation of extracellular regulated kinase pathway. J. Virol. 77, 5493–5498 (2003). · DOI
  37. Saito, A. & Kamatani, N. Strategies for genome-wide association studies: optimization of study designs by the stepwise focusing method. J. Hum. Genet. 47, 360–365 (2002). · DOI
  38. Skol, A.D. et al. Joint analysis is more efficient than replication-based analysis for two-stage genome-wide association studies. Nat. Genet. 38, 209–213 (2006). · DOI · Paper page
  39. Bersaglieri, T. et al. Genetic signatures of strong recent positive selection at the lactase gene. Am. J. Hum. Genet. 74, 1111–1120 (2004). · DOI · Paper page
  40. Coelho, M. et al. Microsatellite variation and evolution of human lactase persistence. Hum. Genet. 117, 329–339 (2005). · DOI
  41. Sasieni, P.D. From genotype to genes: doubling the sample size. Biometrics 53, 1253–1261 (1997). · DOI · Paper page
  42. Barrett, J.C., Fry, B., Maller, J. & Daly, M.J. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21, 263–265 (2005). · DOI · Paper page

Cited by

See all 1,826

Metadata

Authors
Study, F. T. H. C., Suppiah, V., Moldovan, M., Ahlenstiel, G., Berg, T., Weltman, M., Abate, M. L., Bassendine, M., Spengler, U., Dore, G. J., Powell, E., Riordan, S., Sheridan, D., Smedile, A., Fragomeli, V., Müller, T., Bahlo, M., Stewart, G. J., Booth, D. R., & George, J.
Venue
Nature Genetics
Publisher
Springer Science and Business Media LLC
Published
2009-09-13
Volume
41
Issue
10
Pages
1100-1104
ISSN
  • 1061-4036 (ISSN-L)
  • 1546-1718
DOI
10.1038/ng.447
OpenAlex
W2086414517
Cited by
1,826
References
7
FWCI
152.82
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy. https://app.cochat.ai/papers/10.1038/ng.447
The paper
Study, F. T. H. C., Suppiah, V., Moldovan, M., Ahlenstiel, G., Berg, T., Weltman, M., Abate, M. L., Bassendine, M., Spengler, U., Dore, G. J., Powell, E., Riordan, S., Sheridan, D., Smedile, A., Fragomeli, V., Müller, T., Bahlo, M., Stewart, G. J., Booth, D. R., & George, J. (2009). IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy. Nature Genetics. https://doi.org/10.1038/ng.447

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.